John Berriman, chairman of the board of directors at ReNeuron Group Plc, has been named as a director of Autolus Ltd, a UK company investigating T cell therapies for cancer. Mr Berriman was a director of Micromet Inc until its sale to Amgen in 2012 and since that time also chaired Heptares Therapeutics Ltd and Algeta ASA, which were sold respectively to Sosei Group Corp in 2015 and to Bayer AG in 2014.
Also named director is Kapil Dhingra of KAPital Consulting, a healthcare consulting firm that he founded in 2008. Dr Dhingra previously was vice president of oncology clinical development at Hoffmann-La Roche Inc.
Autolus announced the appointments on 6 May 2015.
Copyright 2015 Evernow Publishing Ltd